SI-Bone price target raised to $22 from $18 at Truist

Truist raised the firm’s price target on SI-Bone (SIBN) to $22 from $18 and keeps a Buy rating on the shares after its Q4 results. The company has complemented its preannounced revenue beat with gross margin and EBITDA upside, with the positives in the quarter that include improving sales force productivity, a growing active surgeon base, a rapid Granite 9.5 rollout, and rising per physician utilization, the analyst tells investors in a research note. Truist adds that SI-Bone is primed to beat consensus and raise guidance through FY25.